INBS Stock Risk & Deep Value Analysis
Intelligent Bio Solutions Inc
Healthcare • Medical Devices
DVR Score
out of 10
What You Need to Know About INBS Stock
We analyzed Intelligent Bio Solutions Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran INBS through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
INBS Risk Analysis & Red Flags
What Could Go Wrong
The company's future hinges entirely on successfully navigating the remaining FDA clinical studies and securing regulatory approval for its fingerprint drug screening technology. Any delays or failure in these studies, or an inability to raise further capital without excessive dilution (especially given the current $3.9M ATM on a $10M market cap), would severely jeopardize its commercial prospects and likely lead to a significant decline in share value.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
High
Regulatory
High
Red Flags
- ⚠
Implied negative cash flow and ongoing dilution risk via a substantial ATM offering.
- ⚠
Lack of comprehensive, real-time financial data (e.g., margins, FCF, liquidity ratios).
- ⚠
Extreme reliance on a single regulatory approval for the core product's commercial viability.
- ⚠
No analyst coverage or reported institutional ownership to validate the investment thesis.
Upcoming Risk Events
- 📅
Delays or negative results from ongoing FDA clinical studies
- 📅
Inability to secure sufficient capital without excessive dilution
- 📅
Intensified competition from established players or new technologies
When to Reconsider
- 🚪
Failure to complete FDA Phase 2 or Interference studies on schedule or with positive results.
- 🚪
Announcement of significant delays or adverse trial outcomes leading to a prolonged approval timeline.
- 🚪
Substantial equity raise leading to >50% dilution without a clear path to profitability.
- 🚪
Cash balance falling below 6 months of implied burn rate without new financing.
Unlock INBS Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Intelligent Bio Solutions Inc (INBS) Do?
Market Cap
$11.03M
Sector
Healthcare
Industry
Medical Devices
Employees
53
Intelligent Bio Solutions Inc., a medical technology company, focused on developing and delivering non-invasive testing, and screening solutions in Asia Pacific, the United States, the United Kingdom, and internationally. The company operates intelligent fingerprinting drug screening system, a platform to analyze fingerprint sweat analysis to detect drugs abuse; and biosensor platform. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. Intelligent Bio Solutions Inc. was incorporated in 2016 and is headquartered in New York, New York.
Visit Intelligent Bio Solutions Inc WebsiteInvestment Thesis
Intelligent Bio Solutions Inc. presents a compelling high-risk, high-reward opportunity rooted in its proprietary non-invasive fingerprint drug screening technology. With recent progress in FDA clinical studies and expected significant revenue growth, the company is strategically positioned to disrupt the traditional drug testing market by offering a rapid, cost-effective, and hygienic solution, driving significant market share gains if regulatory hurdles are cleared and commercial adoption materializes.
Is INBS Stock Undervalued?
Unlock the full AI analysis for INBS
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
INBS Price Targets & Strategy
12-Month Target
$18.00
Bull Case
$40.00
Bear Case
$1.00
Valuation Basis
Based on 8x P/S multiple on estimated $4.5M FY2027 revenue, assuming successful FDA path and initial commercialization, with a conservative diluted share count of 2.5M.
Entry Strategy
Dollar-cost average on dips towards recent support levels, maintaining a small initial position given the high risk. Entry below $3.00 is attractive before further FDA news.
Exit Strategy
Take partial profits at $10-$12 (first 4-5x potential), with a stop-loss order below $2.00 if FDA progress stalls or cash concerns escalate.
Portfolio Allocation
1-3% for aggressive risk tolerance (speculative position).
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is INBS Financially Healthy?
Valuation
P/E Ratio
-0.80
Forward P/E
15.40
PEG Ratio
-0.01
Price/Book
2.00
Price/Sales
0.80
Profitability
Return on Equity
-233.66%
Revenue Growth
48.00%
EPS
$-2.00
Balance Sheet
Current Ratio
0.89
Quick Ratio
0.65
Debt/Equity
0.17
Does INBS Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
1 Identified
The moat's durability depends heavily on successfully securing FDA approval and establishing a strong market presence before competitors develop similar non-invasive technologies or traditional methods adapt. The current IP provides a significant head start and barrier to entry.
Moat Erosion Risks
- •Failure to obtain FDA approval or significant delays in the process.
- •Emergence of superior or equally effective competing non-invasive technologies.
- •Rapid commoditization of drug testing services reducing pricing power.
INBS Competitive Moat Analysis
Sign up to see competitive advantages
INBS Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (due to micro-cap status and limited public discourse data)
Institutional Sentiment
Neutral (no analyst coverage or institutional ownership reported)
Insider Activity (Form 4)
March 18, 2026: CEO Harry Simeonidis granted 9,150 time-vesting restricted shares and 21,350 performance-vesting shares. CFO granted 9,150 time-vesting shares and 21,350 performance-vesting shares. Director Jason Isenberg granted 5,000 time-vesting restricted shares. Other non-employee directors and employees also received grants. No open-market buys/sells reported.
Options Flow
Normal options activity (no specific unusual activity reported in research)
Earnings Intelligence
Next Earnings
Estimated early-May 2026 (for Fiscal Q2 2026)
Surprise Probability
Medium (management guiding strong revenue growth, but no consensus estimates for comparison)
Historical Earnings Pattern
No historical earnings reaction patterns available; likely volatile given micro-cap status.
Key Metrics to Watch
Competitive Position
Top Competitor
DGX (Quest Diagnostics)
Market Share Trend
Too early to assess; pre-commercial for its primary growth product.
Valuation vs Peers
Cannot be definitively assessed due to lack of standard valuation multiples and peer-specific data for INBS. Likely trading at a high speculative premium on future potential rather than current fundamentals.
Competitive Advantages
- •Proprietary non-invasive fingerprint drug screening technology (Intangible Assets/IP)
- •Potential for rapid, on-site testing with high accuracy
- •Hygienic and user-friendly testing experience compared to traditional methods
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive INBS Stock Higher?
Near-Term (0-6 months)
- •Fiscal Q2 2026 Earnings (expected early-May 2026, guiding ~48% YoY revenue growth)
- •Completion of FDA Phase 2 Clinical Study (expected June 2026)
- •Completion of FDA Interference Study (expected July 2026)
Medium-Term (6-18 months)
- •Potential FDA approval for fingerprint drug screening system (H2 2026 / H1 2027)
- •Announcement of initial commercial contracts or strategic partnerships
- •Market expansion efforts into key sectors (e.g., workplace, government)
Long-Term (18+ months)
- •Widespread adoption of non-invasive fingerprint drug screening disrupting traditional methods
- •Expansion into international markets
- •Development of additional non-invasive diagnostic solutions
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for INBS?
- ✓
Timely completion and positive outcomes of FDA Phase 2 and Interference studies.
- ✓
Acceleration in commercial contract wins and initial revenue generation post-FDA approval.
- ✓
Improvement in cash burn rate and a clear path to sustainable profitability.
Bull Case Analysis
See what could go right with Premium
Competing with INBS
See how Intelligent Bio Solutions Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Intelligent Bio Solutions Inc INBS | $11.0M | 5.5 | -0.8 | $3.1M | 0.0% | 48.0% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Intelligent Bio Solutions Inc Makes Money
Intelligent Bio Solutions Inc. develops and commercializes non-invasive drug screening solutions, primarily utilizing its proprietary fingerprint-based technology. This technology allows for rapid, on-site detection of drug use by analyzing sweat from fingerprints, aiming to provide a more hygienic, convenient, and cost-effective alternative to traditional urine or blood tests. The company currently generates some revenue from other biosolutions, but its significant growth potential lies in the future commercialization of its fingerprint drug screening system, targeting sectors like workplace drug testing, clinical diagnostics, and government agencies.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Intelligent Bio Solutions Inc (INBS)?
As of April 9, 2026, Intelligent Bio Solutions Inc has a DVR Score of 5.5 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Intelligent Bio Solutions Inc?
Intelligent Bio Solutions Inc's market capitalization is approximately $11.0M. The company operates in the Healthcare sector within the Medical Devices industry.
What ticker symbol does Intelligent Bio Solutions Inc use?
INBS is the ticker symbol for Intelligent Bio Solutions Inc. The company trades on the NCM.
What is the risk level for INBS stock?
Our analysis rates Intelligent Bio Solutions Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of INBS?
Intelligent Bio Solutions Inc currently has a price-to-earnings (P/E) ratio of -0.8. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Intelligent Bio Solutions Inc's revenue growing?
Intelligent Bio Solutions Inc has reported revenue growth of 48.0%. The company is showing strong top-line momentum.
Is INBS stock profitable?
Intelligent Bio Solutions Inc has a profit margin of 0.0%. The company is currently unprofitable.
How often is the INBS DVR analysis updated?
Our AI-powered analysis of Intelligent Bio Solutions Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 9, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for INBS (Intelligent Bio Solutions Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.